Alvisĭ V, D'Ambrosi A, Lo Ponte A, Tampieri M L, Tralli M
Arch Sci Med (Torino). 1980 Oct-Dec;137(4):731-8.
The results of a clinical trial on both tolerance and therapeutic effect of ACTA (Arginine-Thiazolidine-Carboxylate) are reported. Thirty patients were treated wih the drug according to a standard administration scheme: 1,2 g of Arginine-Thiazolidine-Carboxylate per day for 60 days. Statistical evaluation has shown, in comparison with the basal values, highly significant differences at the end of the treatment for the parameters of the so-called "cytolytic syndrome". The concept of membrane-protecting action against lipo-peroxydation, exerted by ATCA is also confirmed by the ultra-structural pictures obtained from bioptic liver specimens.
本文报告了关于ACTA（精氨酸-噻唑烷羧酸盐）耐受性和治疗效果的一项临床试验结果。30名患者按照标准给药方案接受该药物治疗：每天服用1.2克精氨酸-噻唑烷羧酸盐，持续60天。统计评估显示，与基础值相比，在治疗结束时，所谓“细胞溶解综合征”参数有极显著差异。从肝活检标本获得的超微结构图片也证实了ATCA对脂质过氧化具有膜保护作用的概念。
